Home Newsfeeds JMP Securities Downgrades iBio to Market Perform

JMP Securities Downgrades iBio to Market Perform

JMP Securities analyst Roy Buchanan downgrades iBio (AMEX:IBIO) from Market Outperform to Market Perform.

byBenzinga Newsdesk

February 16, 2023

1 minute read

JMP Securities analyst Roy Buchanan downgrades iBio (AMEX:IBIO) from Market Outperform to Market Perform.

Analyst Ratings

4 Analysts Have This to Say About GE HealthCare Techs

By Benzinga Insights

July 26, 4:00 PM

GE HealthCare Techs (NASDAQ:GEHC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

GEHC

Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card

By Benzinga Newsdesk

May 1, 3:05 PM

Strong NovaSeqTM X shipments drove solid Illumina first quarter results; company commits to grow Core Illumina non-GAAP operating margins to 27%[1] in 2025Announces more than $100 million in annualized cost

ILMN

Credit Suisse Downgrades Oatly Group to Neutral, Lowers Price Target to $3.43

By Benzinga Newsdesk

September 13, 5:14 AM

Credit Suisse analyst Kaumil Gajrawala downgrades Oatly Group (NASDAQ:OTLY) from Outperform to Neutral and lowers the price target from $6 to $3.43.

OTLY

AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance

By Vandana Singh

June 15, 11:39 AM

AbbVie Inc (NYSE: ABBV) announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in moderately to

ABBV

JMP Securities Downgrades iBio to Market Perform

Related Posts

4 Analysts Have This to Say About GE HealthCare Techs

Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card

Credit Suisse Downgrades Oatly Group to Neutral, Lowers Price Target to $3.43

AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance